<div id="readability-page-1">Salarius Pharmaceuticals Inc. ( SLRX ) shares surged 23.65% in after-hours trading on Tuesday, closing at $1.21. The Houston-based biopharmaceutical company's stock jumped after it released pricing details for its underwritten public offering. Check out the current price of SLRX stock here. According to Benzinga Pro data, the stock dropped 51% in the regular trading session to close Tuesday at $0.98. <h2>$7 Million Offering Details</h2> Salarius stated in a press release on Tuesday that it priced an underwritten public offering with the goal of raising roughly $7 million in gross proceeds before fees. The offering comprises 2.51 million common stock shares and pre-funded warrants to purchase 2.15 million shares at a combined offering price of $1.50 per share with accompanying Series A and Series B warrants. <h2>Warrant Structure and Terms</h2> The exercise price for both warrant series is $1.50. Series B warrants have a one-year exercise window, whereas Series A warrants are exercisable for five years after issuance. The filing states that the warrants have fixed pricing with no variable pricing features. <h2>Merger-Contingent Closing</h2> The completion of Salarius’ proposed business combination with Decoy Therapeutics Inc., a preclinical-stage biotechnology company, is a prerequisite for the offering’s closing, which is anticipated on Wednesday. Ladenburg Thalmann &amp; Co. Inc. serves as the sole book-running manager. Salarius plans to use the proceeds to fund research programs, repay Decoy's promissory notes, and cover working capital needs. <h2>Stock Performance</h2> The stock of the clinical-stage company is down 96.25% year to date. The company has a market capitalization of $1.03 million and an average daily trading volume of 318,090 shares. Benzinga Edge Stock Rankings indicate that SLRX has a negative price trend across all time frames. Track the performance of other players in this segment. &lt;figure class=&#34;wp-block-image aligncenter size-full is-resized&#34;&gt;<img width="534" height="337" src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2025/11/11214026/image-242.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2025/11/11214026/image-242.png"/>&lt;/figure&gt; Read Next: <ul> <li>Cathie Wood Goes Big On Alibaba With $25 Million Share Purchase, Scales Back On This Social Media Stock</li> </ul> Photo Courtesy: BEST-BACKGROUNDS on Shutterstock.com Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</div>

SLRX

Salarius Pharmaceuticals Inc. (SLRX) 的股票在盤後交易中上漲了 23.65%，至 1.21 美元，此次上漲是由於宣佈了一項 700 萬美元的承銷公開發行。該發行包括 251 萬股普通股和 215 萬股預先融資的認股權證，每股價格為 1.50 美元。此次發行的完成取決於與 Decoy Therapeutics Inc. 的合併。儘管盤後交易大幅上漲，SLRX 股票年初至今仍下跌了 96.25%，市值為 103 萬美元

為什麼 Salarius (SLRX) 的股價在盤後交易中飆升超過 23%？